A novel crystalline form of 6-hydroxy-3-(4-2-(piperidin-1-yl)ethoxyphenoxy)-2-(4-methoxyphenyl)benzobthiophene hydrochloride
CA 2314682 A1 · Owner: Eli Lilly And Company · Inventors: Luke, Wayne Douglas; Conrad, Preston Charles; Bush, Julie Kay
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention is directed to a novel crystalline hydrate of 6-hydroxy-3-(4-2-(piperidin-1yl)ethoxyphenoxy)-2-(4-methoxyphenyl)benzobthiophene hydrochloride and uses for same, including inhibition of disease states associated with estrogen deprivation including cardiovascular disease, hyperlipidemia and, osteoporosis; and inhibition of other pathological conditions such as endometriosis, uterine fibrosis estrogen-dependent cancer (including breast and uterine cancer), prostate cancer, benign prostatic hyperplasia CNS, disorders including Alzheimer's disease prevention of, breast cancer, and up-regulating ChAT.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 28, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 28, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 28, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.